SUN-170 Development of Type 1 Diabetes Mellitus on Immune Checkpoint Inhibitor

Introduction: Immune checkpoint inhibitors (ICPi) are used to augment the immune response and have led to improved outcomes in various malignancies. With this enhanced immunologic response comes a spectrum of side effects, known as immune-related adverse events (iRAEs). These are most commonly derma...

Full description

Saved in:
Bibliographic Details
Published in:J Endocr Soc
Main Authors: Tsuei, Jessica, Kwan, Christina, Kirkeby, Kjersti
Format: Artigo
Language:Inglês
Published: Endocrine Society 2019
Subjects:
Diabetes Mellitus and Glucose Metabolism
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553242/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-170
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items